Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that the Akt inhibitor GDC-0068 may be an encouraging targeted treatment strategy for breast cancer brain metastasis patients with activating mutations in the PI3K pathway.
|
31173106 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
LYN(D189Y) overexpression abrogated growth inhibition by fulvestrant and/or the PI3K inhibitor BKM120 in 3 ER(+) breast cancer cell lines.
|
25401474 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in the PI3K p110 catalytic subunit (PIK3CA) have been identified in 18-40 % of breast carcinomas.
|
27282497 |
2016 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with cancer and phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene mutations have been observed in 25-45% of breast cancer samples.
|
25422220 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
|
26995633 |
2016 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Though incidence of PI3K oncogenic mutation is prominent in breast cancer (20-30%), pharmacological targeting of this signaling pathway alone has failed to provide meaningful clinical benefit.
|
28902361 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
|
20471474 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations are frequent in breast cancer and activate the PI3K/Akt pathway.
|
20940279 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The gain-of-function mutations in the PI3K p110 catalytic subunit (PIK3CA) have been identified in many cancers with a current global incidence of 26% (18-40%) in breast carcinomas.
|
23982433 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The gene encoding for PI3K catalytic subunit p110α is mutated in 20-40% of BC.
|
29345357 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Estrogen dependence is major driver of ER + breast cancer, which is associated with PI3K mutation.
|
30076411 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidemiologic studies suggested that mutations of the PI3K/PTEN/AKT pathway genes are associated with cancer risk, yet no data are available for PTEN rs701848, PIK3CA rs2699887, and AKT1 rs2494752 polymorphism and breast cancer(BC) risk.
|
28423632 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, our findings show that triple negative breast cancers with apocrine differentiation constitute a distinct subset, characterized by a high frequency of PI3K pathway alterations similar to luminal subtypes of breast cancer.
|
26939876 |
2016 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on <i>TP53</i> mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway.
|
28454214 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
|
25002028 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that combining mTOR and DNA repair inhibition could be a successful strategy to treat a subset of breast cancer with BRCA2 mutation and alterations in the PI3K/AKT/mTOR pathway.
|
30038706 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
|
24601221 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
|
23903756 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In univariate analysis, PI3K pathway aberrations were associated with death from breast cancer; however, this relationship was not maintained in multivariate analysis.
|
19685490 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
|
28296140 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors.
|
20479250 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The trial investigated the safety and efficacy of the AR-antagonist enzalutamide alone or in combination with the PI3K inhibitor taselisib in patients with metastatic AR+ (≥10%) breast cancer.
|
31822498 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations are common activating mutations associated with breast cancer (occurring in 20-30% of all cases) and are potent predictive markers for responses to PI3K inhibitors.
|
29906308 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Collectively, these findings advance our understanding of PI3K impactful mutations in breast cancer and have important implications for PI3K-targeted therapy in precision oncology.
|
29636477 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in breast cancer, with mutations in PIK3CA being the most common.
|
25199759 |
2014 |